HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
Benzinga Newsdesk 9 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.